Marc Lemaître Appointed CEO of Girindus America, Inc.‎

Marc Lemaître Appointed CEO of Girindus America, Inc.‎

Cincinnati / Bergisch Gladbach, November 30, 2009. Girindus, a service provider to the pharmaceutical industry for APIs and a leading manufacturer of therapeutic oligonucleotides, is pleased to announce the appointment of Dr. Marc Lemaître as CEO of Girindus America, Inc. starting December 1st, 2009. In this role, Dr. Lemaître will lead Girindus' US operation and will have direct managerial responsibility for all business development and R&D activities.

Dr. Lemaître holds a diploma in Organic Chemistry and received a Doctorate of Science in Biochemistry from the University of Liège in Belgium. After post-doctoral work in Montpellier, France, and two years at the Institute Pasteur (Paris) working in the lab of Dr. Luc Montagnier (2008 Nobel Prize in Medicine), Dr. Lemaître began his industrial career at Rhone-Poulenc-Rorer (now part of Sanofi-Aventis). He then moved to Eurogentec and further to Glen Research. Dr. Lemaître has been engaged in the fields of biotechnology research and production, QC, quality management and business development for over 20 years. During that time, he has maintained a strong focus on oligonucleotides, publishing over 50 technical papers in the areas of antisense oligonucleotides, q-PCR, siRNA, antiviral nucleosides and other related technologies.

"Marc brings with him broad experience in the oligonucleotide arena as well as a deep understanding of our industry. I am pleased that we were able to bring to Girindus a person with such a unique background and look forward to his leadership of both the technology and business aspects", said Martin Weiland, Speaker of the Management Board of Girindus AG.

Markus Georgi
Investor Relations & Public Relations
Girindus AG, 51427 Bergisch Gladbach
T: +49 (0)2204 - 926 900
F: +49 (0)2204 - 926 990
[email protected]



Suggested Articles

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development. 

In a pandemic world, the biotech funding environment couldn’t look brighter, and today Pfizer shone its own light.